Trial Title: OPT-BIRISKStudy Type: Multicenter, double-blind, randomized trial Objective: To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in … Read More
acute coronary syndrome
ULTIMATE-DAPT: Ticagrelor Monotherapy after ACS
“ULTIMATE-DAPT” trial summary. It presents the results of a clinical trial comparing the use of ticagrelor alone versus the combination of ticagrelor and aspirin following percutaneous coronary intervention (PCI) in patients with Acute Coronary Syndrome (ACS) from month 1 to … Read More
CURRENT-OASIS 7: Double Dose Clopidogrel or ASA in ACS
Year: 2010 Title: CURRENT-OASIS 7 Subtitle: Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing PCI for ACS Type of Trial: Double-blind, Randomized Factorial Trial Objective: To evaluate whether a higher dosage of clopidogrel with aspirin (two … Read More
T-PASS Trial: A Shift in Post-Stenting Treatment for ACS
T-PASS Trial Summary The management of Acute Coronary Syndrome (ACS) after stenting has been a hot topic for medical researchers for years. The recent T-PASS Trial in 2023 has shed light on the possible advantages of shifting from the conventional … Read More
SECURE PCI Trial Summary: Loading Atorvastatin in ACS
2018 SECURE-PCI TRIAL Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome double-blind, multicenter, randomized controlled trial Objective: To determine if periprocedural loading doses of atorvastatin decrease 30-day … Read More